Guardant Health Liquid Biopsy Test Gets Expanded Medicare Coverage for Solid Tumors

Guardant Health announced recently that its Guardant360 liquid biopsy test has received expanded Medicare coverage across a dozen solid tumor types. 

Palmetto, the administrative contractor for the Medicare Molecular Diagnostics program, has expanded its local coverage determination (LCD) for Guardant360, effective February 3, 2020. The move makes the test the first and only liquid biopsy to be covered for use across most solid tumors, the firm said in a statement.

The policy covers Guardant360 for all fee-for-service Medicare patients who could benefit from biomarker information being used to inform cancer treatment decisions, but who have insufficient or unavailable tumor tissue for testing.

Source: https://www.genomeweb.com/cancer/guardant-health-liquid-biopsy-test-gets-expanded-medicare-coverage-solid-tumors